Nearly 40% of AstraZeneca investors reject boss’s bonus rise
by Julia Kollewe and Damien Gayle from on (#5HPVG)
Covid vaccine maker passes its remuneration policy but suffers sizeable rebellion
AstraZeneca has suffered a substantial shareholder rebellion over proposals to hand its chief executive, Pascal Soriot, bigger bonus awards for the second consecutive year.
Nearly 40% voted against the policy, which could hand him pay and perks of nearly 18m for 2021.
Continue reading...